Valneva to test vaccine prototype in Japan

Valneva receives approval for EB66(R)-based influenza vaccine in Japan
Valneva receives approval for EB66(R)-based influenza vaccine in Japan | Courtesy of
Valneva SE, a biotechnology company developing pure play vaccines, recently announced that its Chemo-Sero-Therapeutic Research Institute has approval to produce and market an influenza vaccine prototype to help Japan be better protected against pandemics.

When any pandemic happens, Valneva researchers can determine the specific virus strain causing the pandemic and quickly produce and supply the new vaccine.

The prototype vaccine was created with a model virus from Valneva's EB66 line, which was made in collaboration with GlaxoSmithKline and is confirmed for safety and immunogenicity in human subjects. This development was made in a new, state-of-the-art facility in Kumamoto that can create 80 million doses of a vaccine for over 40 million people in just six months.

“This approval constitutes another major achievement and it will provide potential revenue stream for our EB66 platform,” Valneva's CEO Thomas Lingelbach and Chief Business Officer Franck Grimaud said.

Valneva now has over 35 license agreements for use of the EB66 line with several of the largest pharmaceutical companies in the world.

Organizations in this Story

Valneva SE

Want to get notified whenever we write about Valneva SE ?
Next time we write about Valneva SE, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.